A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM31510 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Epidermolysis bullosa; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Berg Pharma
- 04 Apr 2017 Status changed from recruiting to completed.
- 11 Jan 2017 Status changed from not yet recruiting to recruiting.
- 29 Dec 2016 New trial record